Skip to main content

Table 4 28 day mortality of Cefoperazone/Sulbactam monotherapy group and Cefoperazone/Sulbactam based combination therapy group

From: Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

Treatment (Number)

Treatment (Number)

28 day mortality

p value

Sulbactam monotherapy (30)

Cefoperazone/Sulbactam (30)

40% (12/30)

 

Sulbactam based combination therapy (45)

Cefoperazone/Sulbactam+ Imipenem/cilastatin (25)

16% (4/25)

0.048*

Cefoperazone/Sulbactam+ Biapenem or Meropenem (10)

33.3% (3/10)

0.432

Cefoperazone/Sulbactam+ Other antibiotic(10)

33.3% (3/10)

0.432

  1. Note: “*” Asterisks indicate statistically significantly different from Cefoperazone/Sulbactam alone treatment (Chi-square test)